FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294193259> ?p ?o ?g. }

• W4294193259 endingPage "100631" @default.
• W4294193259 startingPage "100631" @default.
• W4294193259 abstract "The prognosis of patients presenting with stage IVB uterine serous carcinoma (USC) remains extremely poor, with a reported 5-year survival of <20%. Here were evaluate the survival impact of cytoreductive surgery and identify other prognostic factors in stage IVB USC.A multicenter retrospective analysis of patients with stage IVB USC was conducted from 2000 to 2018. Inclusion criteria were patients who had undergone comprehensive surgical staging/tumor debulking; followed by adjuvant chemotherapy+/-external beam radiation therapy (EBRT). Optimal cytoreduction (R1) was defined as residual disease ≤1 cm at completion of surgery, and suboptimal cytoreduction (R2) was defined as >1 cm. Progression free survival (PFS) and overall survival (OS) analysis was performed using Kaplan-Meier estimates. Multivariate analysis (MVA) was performed using Cox proportional hazards model.Final analysis included 68 patients. There was no difference in the frequency of treatment delays between regimens (p = 0.832). 96% of patients received platinum-based chemotherapy. There was no difference in the age (p = 0.227), race (p = 0.936), type of radiotherapy (p = 0.852) or chemotherapy regimen received (p = 0.996) between R1 and R2 cohorts. The median PFS for all patients was 8 months and the median OS was 13 months. Cytoreduction to R1 was associated with a median PFS of 9 months, compared to R2 with a median PFS of 4 months (p < 0.001, HR 0.32, 95% CI 7.4-14.1). Median OS was also improved with R1 vs. R2 cytoreduction (17 months vs. 7 months, respectively) (p < 0.001, HR 0.21, 95% CI 13.7-26.4). Compared to R1, cytoreduction to R0 was not associated with a survival benefit. The R0 median OS was 17 months versus 18 months in R1 (p = 0.67). The combination of adjuvant chemoradiation was associated with improved PFS (11 months vs. 7 months) (p = 0.024, HR 0.41, 95% CI 6.5-9.4) and OS (22 months vs 13 months) (p = 0.65, HR 0.25, 95% CI 10.5-15.4) compared to chemotherapy-alone, respectively. On MVA, only the amount of residual disease (p = 0.003, HR 0.39, 95% CI 0.2-0.7) and receipt of adjuvant chemoradiation (p = 0.010, HR 0.09, 95% CI 0.01-0.58) were independent predictors of survival.In stage IVB USC, optimal cytoreduction should be the goal at the time of primary surgery. The combination of chemoradiation was associated with superior survival compared to chemotherapy alone and should be further investigated in this patient population." @default.
• W4294193259 created "2022-09-02" @default.
• W4294193259 creator A5015878721 @default.
• W4294193259 creator A5018485112 @default.
• W4294193259 creator A5019500474 @default.
• W4294193259 creator A5020544372 @default.
• W4294193259 creator A5023740138 @default.
• W4294193259 creator A5031926434 @default.
• W4294193259 creator A5079276713 @default.
• W4294193259 date "2022-01-01" @default.
• W4294193259 modified "2023-10-18" @default.
• W4294193259 title "Optimal cytoreduction followed by chemoradiation in stage IVB uterine serous carcinoma" @default.
• W4294193259 cites W1968878817 @default.
• W4294193259 cites W1973820568 @default.
• W4294193259 cites W1991716175 @default.
• W4294193259 cites W1995318474 @default.
• W4294193259 cites W1998466115 @default.
• W4294193259 cites W2010616025 @default.
• W4294193259 cites W2023054982 @default.
• W4294193259 cites W2025372445 @default.
• W4294193259 cites W2028631125 @default.
• W4294193259 cites W2045612810 @default.
• W4294193259 cites W2046089575 @default.
• W4294193259 cites W2051937776 @default.
• W4294193259 cites W2065949107 @default.
• W4294193259 cites W2069407993 @default.
• W4294193259 cites W2079169660 @default.
• W4294193259 cites W2118510249 @default.
• W4294193259 cites W2154885792 @default.
• W4294193259 cites W2169183724 @default.
• W4294193259 cites W2794839527 @default.
• W4294193259 cites W2804300935 @default.
• W4294193259 cites W2910174605 @default.
• W4294193259 cites W2949349304 @default.
• W4294193259 cites W2963015093 @default.
• W4294193259 cites W3037541659 @default.
• W4294193259 cites W3082773691 @default.
• W4294193259 cites W3128010851 @default.
• W4294193259 cites W3194293897 @default.
• W4294193259 doi "https://doi.org/10.1016/j.ctarc.2022.100631" @default.
• W4294193259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36096033" @default.
• W4294193259 hasPublicationYear "2022" @default.
• W4294193259 type Work @default.
• W4294193259 citedByCount "0" @default.
• W4294193259 crossrefType "journal-article" @default.
• W4294193259 hasAuthorship W4294193259A5015878721 @default.
• W4294193259 hasAuthorship W4294193259A5018485112 @default.
• W4294193259 hasAuthorship W4294193259A5019500474 @default.
• W4294193259 hasAuthorship W4294193259A5020544372 @default.
• W4294193259 hasAuthorship W4294193259A5023740138 @default.
• W4294193259 hasAuthorship W4294193259A5031926434 @default.
• W4294193259 hasAuthorship W4294193259A5079276713 @default.
• W4294193259 hasBestOaLocation W42941932591 @default.
• W4294193259 hasConcept C121608353 @default.
• W4294193259 hasConcept C126322002 @default.
• W4294193259 hasConcept C141071460 @default.
• W4294193259 hasConcept C143998085 @default.
• W4294193259 hasConcept C146357865 @default.
• W4294193259 hasConcept C150173356 @default.
• W4294193259 hasConcept C151730666 @default.
• W4294193259 hasConcept C207103383 @default.
• W4294193259 hasConcept C2775908122 @default.
• W4294193259 hasConcept C2776694085 @default.
• W4294193259 hasConcept C2777416452 @default.
• W4294193259 hasConcept C2780427987 @default.
• W4294193259 hasConcept C2780739268 @default.
• W4294193259 hasConcept C2781100745 @default.
• W4294193259 hasConcept C2781413609 @default.
• W4294193259 hasConcept C44249647 @default.
• W4294193259 hasConcept C50382708 @default.
• W4294193259 hasConcept C509974204 @default.
• W4294193259 hasConcept C71924100 @default.
• W4294193259 hasConcept C86803240 @default.
• W4294193259 hasConceptScore W4294193259C121608353 @default.
• W4294193259 hasConceptScore W4294193259C126322002 @default.
• W4294193259 hasConceptScore W4294193259C141071460 @default.
• W4294193259 hasConceptScore W4294193259C143998085 @default.
• W4294193259 hasConceptScore W4294193259C146357865 @default.
• W4294193259 hasConceptScore W4294193259C150173356 @default.
• W4294193259 hasConceptScore W4294193259C151730666 @default.
• W4294193259 hasConceptScore W4294193259C207103383 @default.
• W4294193259 hasConceptScore W4294193259C2775908122 @default.
• W4294193259 hasConceptScore W4294193259C2776694085 @default.
• W4294193259 hasConceptScore W4294193259C2777416452 @default.
• W4294193259 hasConceptScore W4294193259C2780427987 @default.
• W4294193259 hasConceptScore W4294193259C2780739268 @default.
• W4294193259 hasConceptScore W4294193259C2781100745 @default.
• W4294193259 hasConceptScore W4294193259C2781413609 @default.
• W4294193259 hasConceptScore W4294193259C44249647 @default.
• W4294193259 hasConceptScore W4294193259C50382708 @default.
• W4294193259 hasConceptScore W4294193259C509974204 @default.
• W4294193259 hasConceptScore W4294193259C71924100 @default.
• W4294193259 hasConceptScore W4294193259C86803240 @default.
• W4294193259 hasLocation W42941932591 @default.
• W4294193259 hasLocation W42941932592 @default.
• W4294193259 hasLocation W42941932593 @default.
• W4294193259 hasOpenAccess W4294193259 @default.
• W4294193259 hasPrimaryLocation W42941932591 @default.

• next